Brief: Reviva Announces Publication On Clinical Vocal Biomarker Data From The Recover Phase 3 Clinical Trial Of Brilaroxazine
08/01/2026 13:22
Jan 8 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O: REVIVA ANNOUNCES PUBLICATION ON CLINICAL VOCAL BIOMARKER DATA FROM THE RECOVER PHASE 3 CLINICAL TRIAL OF BRILAROXAZINE TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Source text: ID:nGNX5Rf0Bz Further company coverage: RVPH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reviva Pharmaceuticals Holdings
See all newsReviva Pharmaceuticals Q1 net loss narrows on lower expenses
Brief: Reviva Pharmaceuticals Holdings Inc - To Be Delisted From Nasdaq Trading Suspended As Of May 14, 2026 - SEC Filing
Brief: Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture